Corvus Pharmaceuticals Inc Stock
Corvus Pharmaceuticals Inc dominated the market today, gaining €0.32 (4.460%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Corvus Pharmaceuticals Inc.
As a result the target price of 10 € shows a positive potential of 33.33% compared to the current price of 7.5 € for Corvus Pharmaceuticals Inc.
For the coming years our community has positive and negative things to say abot the Corvus Pharmaceuticals Inc stock. Criterium "Brand" gathered the most positive votes but regarding "Brand" there were negative voices in the community.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | 4.460% | -2.724% | 15.920% | -1.704% | 54.321% | 695.165% | 128.659% |
| Ardelyx Inc. | -1.090% | 1.501% | 6.242% | -4.991% | 3.525% | 200.937% | -1.306% |
| Krystal Biotech | 1.290% | 6.399% | 17.592% | 14.742% | 32.194% | 183.380% | - |
| Evolus Inc | -1.720% | -2.521% | -4.132% | -50.847% | -44.762% | -12.782% | 90.164% |
Comments
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Mizuho from $12.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $17.00 price target on the stock, up previously from $15.00.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
Show more
Ratings data for CRVS provided by MarketBeat
News
Corvus (CRVS) Q2 Loss Beats Estimates
Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies, released its earnings results for Q2 2025 on August 7, 2025
